Patent Cliffs and Loss of Exclusivity in Biotech

The Cliff That Defines Pharma Revenue

For profitable drug companies, few events matter more than loss of exclusivity (LOE) — the moment a blockbuster drug loses its patent protection and faces lower-cost competition. Revenue that took years to build can erode dramatically once the cliff arrives. For investors, modeling the patent cliff is central to valuing any company with a major marketed product.

What Protects a Drug

Exclusivity comes from two overlapping sources:

1. Patents. Composition-of-matter, formulation, method-of-use, and other patents protect different aspects of a drug. The composition-of-matter patent is usually the most important, but a thicket of later patents can extend protection.
2. Regulatory exclusivity. Separate from patents, the FDA grants periods of market exclusivity — for example, extended exclusivity for orphan drugs or for new biologics — during which competitors can't be approved.

The effective cliff date is determined by whichever protection lasts longest, and by any patent litigation settlements that set a specific competitor-entry date.

Generics vs. Biosimilars: Different Cliffs

The shape of the cliff depends on the drug type:

• Small-molecule drugs face generics. Once patents expire, generics are cheap to make and substitutable, and erosion is fast and steep — branded sales can fall sharply within a year of generic entry.
• Biologics face biosimilars. Because biologics are complex and biosimilars are expensive to develop and manufacture, erosion is typically slower and shallower than for small-molecule generics, though it still meaningfully pressures revenue and price.

Knowing whether a franchise is a small molecule or a biologic tells you how violent the cliff is likely to be.

How Investors Model the Cliff

To assess patent-cliff exposure for a company you follow:

1. Identify the key products and their LOE dates. Tie each to patent expiry, regulatory exclusivity, and any settled entry dates from litigation.
2. Measure revenue concentration. A company deriving most of its revenue from one drug approaching LOE carries far more risk than a diversified one.
3. Model the erosion curve. Steeper for small molecules, gentler for biologics — and adjust for how many competitors are expected.
4. Assess the replacement pipeline. How a company defends against a cliff is the other half of the story (below).

This analysis draws heavily on a company's 10-K, which discloses key patents and risk factors around exclusivity.

How Companies Defend Against Cliffs

Originators don't passively accept the cliff. Common defenses:

• Next-generation products that shift patients to a newer, still-protected drug.
• New indications via supplemental applications that expand and extend the franchise.
• Lifecycle management — new formulations, combinations, or delivery methods with fresh protection.
• M&A and licensing to refill the pipeline ahead of the cliff.

The credibility of these defenses determines whether a cliff is a manageable transition or a value-destroying event.

Cliffs Create Opportunity Too

A patent cliff is bearish for the originator but bullish for the biosimilar or generic developer entering the market, and sometimes for partners. The same event has opposite implications depending on which side you're analyzing — so map both.

Applying It

For any company with significant product revenue, build a simple LOE map: which products, when they lose protection, how concentrated the revenue is, and how credible the replacement pipeline is. The cliff is one of the few large, predictable events in pharma — its timing is often known years in advance — which makes it both a major risk and a plannable one.

Review a company's marketed products, pipeline, and exclusivity disclosures on its company page, track the approval decisions and earnings that reveal erosion on the catalyst calendar, and consider both the originator and the challengers across the affected indications.